Dolores Piniella

Dolores Piniella

Auto-generated profile, based on publicly available information

Dolores Piniella

Neurological Sciences and Cerebrovascular Research Laboratory, Department of Neurology, Neurology and Cerebrovascular Disease Group, Neuroscience Area of Hospital La Paz Institute for Health Research - IdiPAZ (La Paz University Hospital- Universidad Autónoma de Madrid), Madrid, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2023 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
GIGabriel Torres Iglesias
Gabriel Torres Iglesias
MFMireya Fernandez-Fournier
Mireya Fernandez-Fournier
LBLucía Botella
Lucía Botella
DPDolores Piniella
Dolores Piniella
FLFernando Laso-García
Fernando Laso-García
Laura Otero-OrtegaLaura Otero-Ortega
Laura Otero-Ortega
Multiple sclerosis (MS) is an immune-mediated central nervous system disease whose course is unpredictable. Finding biomarkers that help to better comprehend the disease's pathogenesis is crucial for supporting clinical decision-making. Blood extracellular vesicles (EVs) are membrane-bound particles secreted by all cell types that contain information on the disease's pathological processes. To identify the immune and nervous system-derived EV profile from blood that could have a specific role as biomarker in MS and assess its possible correlation with disease state. Higher levels of T cell-derived EVs and smaller size of neuron-derived EVs were associated with clinical relapse. The smaller size of the oligodendrocyte-derived EVs was related with motor and cognitive impairment. The proteomic analysis identified mannose-binding lectin serine protease 1 and complement factor H from immune system cell-derived EVs as autoimmune disease-associated proteins. We observed hepatocyte growth factor-like protein in EVs from T cells and inter-alpha-trypsin inhibitor heavy chain 2 from neurons as white matter injury-related proteins. In patients with MS, a specific protein profile was found in the EVs, higher levels of alpha-1-microglobulin and fibrinogen β chain, lower levels of C1S and gelsolin in the immune system-released vesicles, and Talin-1 overexpression in oligodendrocyte EVs. These specific MS-associated proteins, as well as myelin basic protein in oligodendrocyte EVs, correlated with disease activity in the patients with MS. Neural-derived and immune-derived EVs found in blood appear to be good specific biomarkers in MS for reflecting the disease state.

1 February 2019 in Neurochemistry International
Verified
Journal Article
Closed access
IIIgnacio Ibáñez
Ignacio Ibáñez
DBDavid Bartolomé-Martín
David Bartolomé-Martín
DPDolores Piniella
Dolores Piniella
CGCecilio Giménez
Cecilio Giménez
FZFrancisco Zafra
Francisco Zafra

Verified
Journal Article
Open access
PDF file
DPDolores Piniella
Dolores Piniella
ARAnia Canseco Rodriguez
Ania Canseco Rodriguez
SVSilvia Vidal
Silvia Vidal
CXClara Xiol
Clara Xiol
ABAranzazu Diaz de Bustamante
Aranzazu Diaz de Bustamante
FZFrancisco Zafra
Francisco Zafra
In this article, we identified a novel epileptogenic variant (G307R) of the gene SLC6A1, which encodes the GABA transporter GAT-1. Our main goal was to investigate the pathogenic mechanisms of this variant, located near the neurotransmitter permeation pathway, and compare it with other variants located either in the permeation pathway or close to the lipid bilayer. The mutants G307R and A334P, close to the gates of the transporter, could be glycosylated with variable efficiency and reached the membrane, albeit inactive. Mutants located in the center of the permeation pathway (G297R) or close to the lipid bilayer (A128V, G550R) were retained in the endoplasmic reticulum. Applying an Elastic Network Model, to these and to other previously characterized variants, we found that G307R and A334P significantly perturb the structure and dynamics of the intracellular gate, which can explain their reduced activity, while for A228V and G362R, the reduced translocation to the membrane quantitatively accounts for the reduced activity. The addition of a chemical chaperone (4-phenylbutyric acid, PBA), which improves protein folding, increased the activity of GAT-1WT, as well as most of the assayed variants, including G307R, suggesting that PBA might also assist the conformational changes occurring during the alternative access transport cycle.